Related Experiment Video
Updated: Mar 8, 2026
13:04
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
14.0K
A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA)
Clinical Chemistry and Laboratory Medicine
|January 21, 2017
Summary
This study introduces a new strategy for interpreting Risk of Ovarian Malignancy Algorithm (ROMA) values. It enhances clinical practice by providing more informative HE4 and CA125 interpretations.
Area of Science:
- Biochemistry
- Clinical Diagnostics
- Oncology
Background:
- Accurate quantification of HE4 and CA125 is crucial for the Risk of Ovarian Malignancy Algorithm (ROMA).
- Current interpretation of ROMA values can be limited by assay variability and analytical measurement ranges (AMR).
Purpose of the Study:
- To propose a novel reporting strategy for ROMA values.
- To enhance the clinical utility of HE4 and CA125 measurements by considering AMR and qualified intervals.
Main Methods:
- Utilized HE4 and CA125 assay data from Abbott and Roche platforms.
- Defined AMRs and qualified intervals for each assay to simulate ROMA values.
- Developed a tiered reporting algorithm based on quantitative HE4 and CA125 levels.
Main Results:
- A three-category reporting system for ROMA values was established.
- Defined specific thresholds for HE4 and CA125 to classify ROMA as 'low risk' or 'undetermined' in pre- and postmenopausal women.
- Demonstrated how assay-specific ranges impact ROMA interpretation.
Conclusions:
- The proposed reporting strategy offers a more informative approach to ROMA value interpretation.
- This strategy aims to improve clinical decision-making in ovarian cancer risk assessment.
- Implementation of this strategy can lead to more precise patient management.
